{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T17:32:14Z","timestamp":1786555934425,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.leukres.2026.108284","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:48:02Z","timestamp":1785426482000},"page":"108284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Arterial stiffness in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: An exploratory prospective observational study"],"prefix":"10.1016","volume":"168","author":[{"given":"Olga","family":"Mulas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sestu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7726-2936","authenticated-orcid":false,"given":"Alessandro","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2350-9980","authenticated-orcid":false,"given":"Eleonora","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Frau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Scuteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108284_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"HM. The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2026.108284_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"issue":"24","key":"10.1016\/j.leukres.2026.108284_bib3","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2026.108284_bib4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-022-00692-8","article-title":"Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network","volume":"12","author":"Sanz","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108284_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/VHRM.S108874","article-title":"Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance","volume":"13","author":"Aghel","year":"2017","journal-title":"Vasc. Health Risk Manag."},{"issue":"3","key":"10.1016\/j.leukres.2026.108284_bib6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2026.108284_bib7","doi-asserted-by":"crossref","first-page":"E159","DOI":"10.1002\/ajh.25102","article-title":"Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: identification of risk factors and the role of prophylaxis","volume":"93","author":"Caocci","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108284_bib8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijcard.2019.10.036","article-title":"Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors","volume":"301","author":"Caocci","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.leukres.2026.108284_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/hemato4030017","article-title":"The direct and indirect effects of tyrosine kinase inhibitors on the cardiovascular system in chronic myeloid leukemia","volume":"4","author":"Costa","year":"2023","journal-title":"Hemato"},{"issue":"29","key":"10.1016\/j.leukres.2026.108284_bib10","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.leukres.2026.108284_bib11","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.clml.2017.07.006","article-title":"Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: long-term follow-up","volume":"17","author":"Aghel","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2026.108284_bib12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijcard.2019.04.051","article-title":"Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention","volume":"288","author":"Caocci","year":"2019","journal-title":"Int. J. Cardiol."},{"issue":"7","key":"10.1016\/j.leukres.2026.108284_bib13","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00277-020-04102-6","article-title":"Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors","volume":"99","author":"Mulas","year":"2020","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108284_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","article-title":"Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV","volume":"126","author":"Saussele","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2026.108284_bib15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00277-023-05556-0","article-title":"The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib","volume":"103","author":"Mulas","year":"2024","journal-title":"Ann. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2026.108284_bib16","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1097\/HJH.0000000000001824","article-title":"Characteristics of healthy vascular ageing in pooled population-based cohort studies: the global metabolic syndrome and artery research Consortium","volume":"36","author":"Nilsson","year":"2018","journal-title":"J. Hypertens."},{"issue":"2","key":"10.1016\/j.leukres.2026.108284_bib17","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s11357-022-00699-w","article-title":"Dilated hypertrophic phenotype of the carotid artery is associated with accelerated age-associated central arterial stiffening","volume":"45","author":"AlGhatrif","year":"2023","journal-title":"Geroscience"},{"issue":"12","key":"10.1016\/j.leukres.2026.108284_bib18","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1161\/HYPERTENSIONAHA.124.23392","article-title":"Aortic-femoral stiffness gradient and cardiovascular risk in older adults","volume":"81","author":"Stone","year":"2024","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.leukres.2026.108284_bib19","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/HYPERTENSIONAHA.124.24816","article-title":"Effects of blood pressure control on arterial stiffness mechanisms in SPRINT: a randomized controlled trial","volume":"82","author":"Pewowaruk","year":"2025","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.leukres.2026.108284_bib20","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jamda.2019.11.014","article-title":"Impact of stiffer arteries on the response to antihypertensive treatment: a longitudinal study of the SardiNIA Cohort","volume":"21","author":"Lakatta","year":"2020","journal-title":"J. Am. Med. Dir. Assoc."},{"issue":"1","key":"10.1016\/j.leukres.2026.108284_bib21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/HJH.0000000000002621","volume":"39","author":"Scuteri","year":"2021","journal-title":"J. Hypertens."},{"issue":"22","key":"10.1016\/j.leukres.2026.108284_bib22","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.3390\/jcm13226811","article-title":"Arterial stiffness as a new predictor of clinical outcome in patients with polycythemia Vera","volume":"13","author":"Mulas","year":"2024","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.leukres.2026.108284_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036253","article-title":"Age-associated increase in growth differentiation factor 15 levels correlates with central arterial stiffness and predicts all-cause mortality in a sardinian population cohort","volume":"14","author":"Oppong","year":"2025","journal-title":"J. Am. Heart Assoc."},{"issue":"7","key":"10.1016\/j.leukres.2026.108284_bib24","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolaemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukaemia","volume":"99","author":"Rea","year":"2014","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.leukres.2026.108284_bib25","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.leukres.2026.108284_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0294438","article-title":"Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors","volume":"18","author":"Wang","year":"2023","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.leukres.2026.108284_bib27","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lym","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2026.108284_bib28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J. Clin. Epidemiol."},{"issue":"25","key":"10.1016\/j.leukres.2026.108284_bib29","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.leukres.2026.108284_bib30","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2026.108284_bib31","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/HJH.0b013e32834fa8b0","article-title":"Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity","volume":"30","author":"Van Bortel","year":"2012","journal-title":"J. Hypertens."},{"issue":"11","key":"10.1016\/j.leukres.2026.108284_bib32","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"41","key":"10.1016\/j.leukres.2026.108284_bib33","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.leukres.2026.108284_bib34","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/ehf2.13897","article-title":"The new HFA\/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity","volume":"9","author":"Di Lisi","year":"2022","journal-title":"ESC Heart Fail."},{"issue":"7","key":"10.1016\/j.leukres.2026.108284_bib35","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.3390\/cancers13071631","article-title":"Multiple myeloma patients undergoing carfilzomib: development and validation of a risk score for cardiovascular adverse events prediction","volume":"13","author":"Astarita","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.leukres.2026.108284_bib36","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"issue":"35","key":"10.1016\/j.leukres.2026.108284_bib37","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2026.108284_bib38","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1002\/ajh.23938","article-title":"Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: data from the FDA adverse event reporting system","volume":"90","author":"Cortes","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2026.108284_bib39","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.leukres.2026.108284_bib40","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000505486","article-title":"Cardiovascular toxicity in cancer patients treated with tyrosine kinase inhibitors: a real-world single-center experience","volume":"98","author":"Novo","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.leukres.2026.108284_bib41","article-title":"Association of estimated pulse wave velocity with cardiovascular disease outcomes and all-cause death-a systematic review and meta-analysis","volume":"12","author":"Li","year":"2025","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.leukres.2026.108284_bib42","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal. Transduct. Target. Ther."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:37:41Z","timestamp":1786552661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626001281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"alternative-id":["S0145212626001281"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108284","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arterial stiffness in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: An exploratory prospective observational study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108284","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108284"}}